Practices, Efficacy, and Reported Side Effects Associated with Isotretinoin Treatment in Palestine
Abdallah Abukhalil,Mai Yousef,Marwa Ammar,Weam Jaghama,Ni'meh Al-Shami,Hani Naseef,Abdullah Rabba
DOI: https://doi.org/10.2147/ppa.s442436
2024-02-23
Patient Preference and Adherence
Abstract:Abdallah Damin Abukhalil, Mai Yousef, &ast Marwa Ammar, &ast Weam Jaghama, &ast Ni'meh Al-Shami, Hani A Naseef, Abdullah K Rabba Department of Pharmacy, Faculty of Pharmacy, Nursing, and Health Professions, Birzeit University, West Bank, State of Palestine &astThese authors contributed equally to this work Correspondence: Abdallah Damin Abukhalil; Ni'meh Al-Shami, Pharmacy Department, Faculty of Pharmacy, Nursing and Health Professions, Birzeit University, West Bank, State of Palestine, Email ; Background: Isotretinoin is a commonly prescribed medication for the treatment of acne. It is associated with serious side effects that require monitoring and adherence by patients and healthcare providers. No studies have been conducted in Palestine to explore isotretinoin prescribing and utilization. Objective: This study aims to evaluate the current clinical practices, adherence to clinical guidelines, efficacy, and reported side effects associated with Isotretinoin treatment in Palestine. Methods: A descriptive cross-sectional online questionnaire-based study using social media platforms (eg, Facebook and Telegram) was conducted among Birzeit University students in April 2023. This study included participants aged ≥ 18 years with a history of isotretinoin treatment; subjects with incomplete data were excluded. Statistical significance was set at P < 0.05. SPSS version 27 was used for data analysis. Results: A total of 548 participants were included in the study, the majority of most of whom were female (96%). The most predominant side effects were cracked, dry lips and xeroderma (96.2%). Moreover, 12% of participants had depression. Most respondents were educated about medication side effects and only 39.1% were counseled about blood donation. Of the 59 sexually active women, only 4 (6.8%) were asked for a recent pregnancy test. A total of 60.2% of dermatologists adhered to the American Academy of Dermatology (AAD) guidelines, and 48.7% ordered the required laboratory tests before initiating isotretinoin treatment. Only 1.7% of pharmacists followed the FDA-suggested protocols for dispensing isotretinoin to childbearing females. Conclusion: Adherence to isotretinoin safety prescribing protocols to provide patient education, monitoring, and ordering of laboratories to ensure patient safety can be improved by adapting policies and protocols in pharmacy and medical practice in Palestine to monitor and enforce adherence when prescribing, dispensing, or taking high-risk medications. Keywords: isotretinoin, acne, guidelines, adherence, side effects Acne is a common skin disorder in adolescents. It can negatively affect patients' quality of life, causing anxiety, depression, and low self-esteem due to lesions or scars, which have cosmetic effects on appearance and self-image. 1 Therefore, treatment with safe and effective medications is the primary goal of both patients and healthcare providers. Isotretinoin is a medication chemically related to retinoic acid and has been used to treat acne for almost 40 years. Isotretinoin has been very effective in patients with severe acne by decreasing the size of the sebaceous glands, reducing sebum production, and decreasing skin scarring and lesions. 2 Oral isotretinoin has shown efficacy in treating moderate and preventing psychosocial effects, prolonging remission, and offering a cure. 2 Isotretinoin is indicated for treatment-refractory and moderate to severe nodulocystic acne, a type of severe inflammatory acne that presents as firm, painful lumps under the skin and red bumps on the skin's surface. Isotretinoin has a promising off-label use in managing seborrhea, seborrheic dermatitis, severe rosacea, chemoprevention of non-melanoma skin cancer in at-risk patients, and advanced photoaging with multiple actinic keratoses. 3 According to the American Academy of Dermatology (AAD) and the European Dermatology Forum, physicians should prescribe isotretinoin for acne treatment for 4–6 months, with a cumulative dose greater than 120 mg/kg, which can be reached by either 0.5–1 mg/kg/day. However, isotretinoin therapy guidelines and duration vary from case to case, according to the severity of acne. Some patients require even higher doses, especially truncal, severe acne, males, and younger patients. 4 These guidelines appended some key points that patients must be enlightened with for safety reassurance during treatment, improved results, and increased patient satisfaction. Isotretinoin has demonstrated superiority over other acne treatments, including antibiotics and other topical products, in improving patient outcomes and satisfaction in reducing inflammation and resol -Abstract Truncated-
medicine, general & internal